OAC
IMDX

OMERS Administration Corp’s Insight Molecular Diagnostics IMDX Stock Holding History

OMERS Administration Corp’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.4K Sell
10,500
-15,664
-60% -$90.9K ﹤0.01% 1071
2025
Q4 		$196K Buy
+26,164
New +$148K ﹤0.01% 915

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

OMERS Administration Corp's IMDX Position: Q1 2026 in Review

OMERS Administration Corp reduced its Insight Molecular Diagnostics (IMDX) stake by 60% in Q1 2026, selling an estimated $90.9K and leaving 10,500 shares worth $34.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

OMERS Administration Corp first reported a position in IMDX in Q4 2025 and has held it in 2 quarters since. The position peaked at $196K in Q4 2025. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • OMERS Administration Corp held 10,500 shares of Insight Molecular Diagnostics worth $34.4K as of Q1 2026.
  • OMERS Administration Corp sold 15,664 Insight Molecular Diagnostics shares in Q1 2026, an estimated $90.9K.
  • Insight Molecular Diagnostics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #1071 holding.
  • OMERS Administration Corp first reported a position in Insight Molecular Diagnostics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Insight Molecular Diagnostics position peaked at $196K in Q4 2025.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.